Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4762461 | 0.82 | HSD11B1 (0.37) | HSD11B1CYP2D6KCNH2HRH3CYP1A2 | |
| SCHEMBL10221907 | 0.78 | MGAT2 (0.37) | HSD11B1CYP2D6KCNH2HRH3CYP1A2 | |
| SCHEMBL18199696 | 0.78 | CYP3A4 (0.40) | HSD11B1CYP2D6KCNH2HRH3CYP1A2 | |
| SCHEMBL18199688 | 0.78 | HSD11B1 (0.39) | HSD11B1CYP2D6KCNH2HRH3CYP1A2 | |
| SCHEMBL13819872 | 0.78 | MGAT2 (0.37) | HSD11B1CYP2D6KCNH2HRH3CYP1A2 | |
| SCHEMBL3476998 | 0.75 | HSD11B1 (0.55) | HSD11B1CYP2D6KCNH2HRH3CYP1A2 | |
| SCHEMBL25063762 | 0.74 | ALOX15 (0.44) | HSD11B1CYP2D6KCNH2HRH3CYP1A2 | |
| SCHEMBL7281394 | 0.74 | CARM1 (0.33) | HRH3TSHR | |
| SCHEMBL6430970 | 0.74 | ACHE (0.33) | HRH3 | |
| SCHEMBL19422114 | 0.73 | HSD11B1 (0.37) | HSD11B1CYP2D6KCNH2HRH3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230029378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230029378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | CBL, XIAP, BTK | HSD11B1 3266/4885CYP2D6 3775/4885KCNH2 4624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.